mRNA Therapeutics and mRNA Vaccines

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. mRNA Therapeutics
3.2.1. Advantages of mRNA Therapeutics
3.2.2. Key Applications of mRNA Therapeutics
3.3. mRNA Vaccines
3.3.1. Advantages of mRNA Vaccines
3.3.2. Key Applications of mRNA Vaccines
3.4. mRNA Delivery Routes
3.5. mRNA Delivery Strategies
3.6. Key Challenges Associated with mRNA Therapeutics and Vaccines
3.7. Future Perspectives

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. mRNA Therapeutics and Vaccines: Overall Market Overview
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Drug Candidate
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Phase of Development and Therapeutic Area
4.2.5. Analysis by Type of Delivery System Used
4.2.6. Analysis by Type of Molecule Encoded
4.2.7. Analysis by Route of Administration
4.2.8. Analysis by Therapeutic Area and Route of Administration
4.2.9. Analysis by Phase of Development, Therapeutic Area and Route of Administration (Grid Representation)

5. COMPETITIVE LANDSCAPE
5.1. mRNA Therapeutics and Vaccines: List of Developers
5.1.1. Analysis by Year of Establishment
5.1.2. Analysis by Company Size
5.1.3. Analysis by Location of Headquarters
5.1.4. Key Players: Analysis by Number of Drug Candidates
5.1.5. Key Players: Analysis by Number of Drug Candidates and Phase of Development
5.1.6. Key Players: Analysis by Number of Drug Candidates and Therapeutic Area
5.1.7. Analysis by Year of Establishment, Company Size and Location of Headquarters (Heat Map Representation)
5.1.8. mRNA Therapeutics and Vaccines: Analysis by Phase of Development and Location of Headquarters (Regional Landscape)

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Key Assumptions and Parameters
6.3. Methodology
6.4. mRNA Therapeutics and Vaccines Developers: Company Competitive Analysis
6.5. mRNA Therapeutics and Vaccines Developers based in North America
6.6. mRNA Therapeutics and Vaccines Developers based in Europe
6.7. mRNA Therapeutics and Vaccines Developers based in Asia-Pacific and Rest of the World

7. DRUG PROFILES
7.1. Chapter Overview
7.2. BNT162b2 (BioNTech / Pfizer)
7.2.1. Drug Overview

7.3. GEMCOVAC-19 (Gennova)
7.3.1. Drug Overview
7.4. mRNA-1273 (Moderna) 
7.4.1. Drug Overview

7.5. LUNAR-COV19 (Arcturus Therapeutics)
7.5.1. Drug Overview

7.6. CVnCOV (CureVac)
7.6.1. Drug Overview

7.7. mRNA-1010 (Moderna)
7.7.1. Drug Overview

7.8. mRNA-1345 (Moderna)
7.8.1. Drug Overview

7.9. mRNA-1647 (Moderna)
7.9.1. Drug Overview

7.10. ARCoV (Walvax)
7.10.1. Drug Overview

8. BIG PHARMA INITIATIVES
8.1. Chapter Overview
8.2. Scope and Methodology

8.3. mRNA Related Initiatives of Big Pharmaceutical Players
8.3.1. Analysis by Portfolio Diversity
8.3.2. Analysis by Phase of Development
8.3.3. Analysis by Target Therapeutic Areas

8.4. Benchmark Analysis of Big Pharmaceutical Players
8.4.1. Spider Web Analysis: Amgen
8.4.2. Spider Web Analysis: AstraZeneca
8.4.3. Spider Web Analysis: Bayer
8.4.4. Spider Web Analysis: BioNTech
8.4.5. Spider Web Analysis: Eli Lilly
8.4.6. Spider Web Analysis: Gilead Sciences
8.4.7. Spider Web Analysis: GlaxoSmithKline
8.4.8. Spider Web Analysis: Merck
8.4.9. Spider Web Analysis: Moderna
8.4.10. Spider Web Analysis: Novartis
8.4.11. Spider Web Analysis: Novo Nordisk
8.4.12. Spider Web Analysis: Pfizer
8.4.13. Spider Web Analysis: Roche
8.4.14. Spider Web Analysis: Sanofi
8.4.15. Spider Web Analysis: Takeda

9. START-UP HEALTH INDEXING
9.1. Chapter Overview
9.2. Start-ups focused on mRNA Therapeutics and Vaccines
9.2.1. Analysis by Location of Headquarters

9.3. Benchmarking of Start-ups

9.4. Startup-Health Indexing
9.4.1. Analysis by Supplier Strength
9.4.2. Analysis by Pipeline Maturity
9.4.3. Analysis by Pipeline Strength
9.4.4. Analysis by Financial Investments
9.4.5. Analysis by Partnership Activity
9.4.6. Start-ups Health Indexing: Roots Analysis Perspective

10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. mRNA Therapeutics and Vaccines: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Status
10.3.3. Analysis by Trial Phase
10.3.4. Analysis by Trial Registration Year and Trial Status
10.3.5. Analysis by Trial Registration Year and Trial Phase
10.3.6. Analysis by Trial Status and Trial Phase
10.3.7. Analysis of Enrolled Patient Population by Trial Registration Year
10.3.8. Analysis by Study Design
10.3.9. Analysis by Type of Sponsor / Collaborator
10.3.10. Most Active Players: Analysis by Number of Registered Trials
10.3.11. Analysis by Therapeutic Area
10.3.12. Analysis by Number of Registered Trials and Geography
10.3.13. Analysis by Number of Registered Trials, Trial Status and Geography
10.3.14. Analysis of Enrolled Patient Population by Geography

11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models

11.3. mRNA Therapeutics and Vaccines: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Therapeutic Area
11.3.5. Analysis by Type of Partnership and Therapeutic Area
11.3.6. Most Active Players: Analysis by Number of Partnerships
11.3.7. Regional Analysis
11.3.7.1. Intercontinental and Intracontinental Agreements
11.3.7.2. Local and International Agreements

12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. mRNA Therapeutics and Vaccines: Funding and Investment
12.3.1. Analysis by Cumulative Year-wise Trend of Funding Instances
12.3.2. Analysis by Cumulative Year-wise Trend of Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Year and Type of Funding
12.3.5. Analysis of Number of Funding Instances and Amount Invested by Therapeutic Area
12.3.6. Analysis of Number of Funding Instances and Amount Invested by Geography (Continent-wise)
12.3.7. Regional Analysis of Number of Funding Instances (Country-wise)
12.3.8. Most Active Players: Analysis by Number of Funding Instances
12.3.9. Most Active Players: Analysis by Total Amount Raised
12.3.10. Most Active Investors: Analysis by Number of Funding Instances
12.3.11. Analysis of Amount Invested by Year and Type of Funding (Grid Representation)

13. PATENT ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. mRNA Therapeutics and Vaccines: Patent Analysis
13.3.1. Analysis by Type of Patent
13.3.2. Analysis by Patent Publication Year
13.3.3. Analysis of Granted Patents by Publication Year
13.3.4. Analysis of Filed Patents by Publication Year
13.3.5. Analysis of Year-wise Filed Patent Applications and Granted Patents
13.3.6. Analysis by Publication Year and Type of Applicant
13.3.7. Analysis by Patent Issuing Authority
13.3.8. Analysis by Patent Age
13.3.9. Analysis by CPC Symbols
13.3.10. Leading Players: Analysis by Number of Patents
13.3.11. Leading Inventors: Analysis by Number of Patents

13.4. mRNA Therapeutics and Vaccines: Patent Benchmarking Analysis
13.4.1. Analysis by Patent Characteristics
13.5. mRNA Therapeutics and Vaccines: Patent Valuation Analysis

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology

14.3. Global mRNA Therapeutics and Vaccines Market, 2022-2035
14.3.1. mRNA Therapeutics and Vaccines Market: Analysis by Route of Administration, 2022, 2030, 2035
14.3.2. mRNA Therapeutics and Vaccines Market: Analysis by Therapeutic Area, 2022, 2030, 2035
14.3.3. mRNA Therapeutics and Vaccines Market: Analysis by Geography, 2022, 2030, 2035
14.3.3.1. mRNA Therapeutics and Vaccines Market in North America, 2022-2035
14.3.3.2. mRNA Therapeutics and Vaccines Market in Europe, 2022-2035
14.3.3.3. mRNA Therapeutics and Vaccines Market in Asia-Pacific, 2022-2035
14.3.3.4. mRNA Therapeutics and Vaccines Market in Latin America, 2022-2035
14.3.3.5. mRNA Therapeutics and Vaccines Market in Middle East and North Africa, 2022-2035

14.4. mRNA Therapeutics and Vaccines Market: Value Creation Analysis
14.5. mRNA Therapeutics and Vaccines Market: Product-wise Sales Forecasts
14.5.1. COMIRNATY
14.5.1.1. Target Patient Population
14.5.1.2. Sales Forecast
14.5.1.3. Net Present Value
14.5.1.4. Value Creation Analysis

14.5.2. Spikevax
14.5.2.1. Target Patient Population
14.5.2.2. Sales Forecast
14.5.2.3. Net Present Value
14.5.2.4. Value Creation Analysis

14.5.3. GEMCOVAC-19
14.5.3.1. Target Patient Population
14.5.3.2. Sales Forecast
14.5.3.3. Net Present Value
14.5.3.4. Value Creation Analysis

14.5.4. ARCoV
14.5.4.1. Target Patient Population
14.5.4.2. Sales Forecast
14.5.4.3. Net Present Value
14.5.4.4. Value Creation Analysis

14.5.5. CVnCoV
14.5.5.1. Target Patient Population
14.5.5.2. Sales Forecast
14.5.5.3. Net Present Value
14.5.5.4. Value Creation Analysis

14.5.6. ARCT-154
14.5.6.1. Target Patient Population
14.5.6.2. Sales Forecast
14.5.6.3. Net Present Value
14.5.6.4. Value Creation Analysis

14.5.7. mRNA-1647
14.5.7.1. Target Patient Population
14.5.7.2. Sales Forecast
14.5.7.3. Net Present Value
14.5.7.4. Value Creation Analysis

14.5.8. mRNA-1345
14.5.8.1. Target Patient Population
14.5.8.2. Sales Forecast
14.5.8.3. Net Present Value
14.5.8.4. Value Creation Analysis

14.5.9. mRNA-1010
14.5.9.1. Target Patient Population
14.5.9.2. Sales Forecast
14.5.9.3. Net Present Value
14.5.9.4. Value Creation Analysis

15. CONCLUSION

16. INTERVIEW AND SURVEY TRANSCRIPTS
16.1. Chapter Overview
16.2. eTheRNA Immunotherapies
16.2.1. Company Snapshot
16.2.2. Interview Transcript: David Ricketts (Director, Business Development)

17. APPENDIX I: TABULATED DATA

18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investment Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Historical Evolution of mRNA
Figure 3.2 Key Applications of mRNA Therapeutics
Figure 4.1 mRNA Therapeutics and Vaccines: Distribution by Phase of Development
Figure 4.2 mRNA Therapeutics and Vaccines: Distribution by Type of Drug Candidate
Figure 4.3 mRNA Therapeutics and Vaccines: Distribution by Therapeutic Area
Figure 4.4 mRNA Therapeutics and Vaccines: Distribution by Phase of Development and Therapeutic Area
Figure 4.5 mRNA Therapeutics and Vaccines: Distribution by Type of Delivery System Used
Figure 4.6 mRNA Therapeutics and Vaccines: Distribution by Type of Molecule Encoded
Figure 4.7 mRNA Therapeutics and Vaccines: Distribution by Route of Administration
Figure 4.8 mRNA Therapeutics and Vaccines: Distribution by Therapeutic Area and Route of Administration
Figure 4.9 mRNA Therapeutics and Vaccines: Distribution by Phase of Development, Therapeutic Area and Route of Administration
Figure 5.1 mRNA Therapeutics and Vaccines Developers: Distribution by Year of Establishment
Figure 5.2 mRNA Therapeutics and Vaccines Developers: Distribution by Company Size
Figure 5.3 mRNA Therapeutics and Vaccines Developers: Distribution by Location of Headquarters
Figure 5.4 Key Players: Distribution by Number of Drug Candidates
Figure 5.5 Key Players: Distribution by Phase of Development
Figure 5.6 Key Players: Distribution by Therapeutic Area
Figure 5.7 mRNA Therapeutics and Vaccines Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 5.8 mRNA Therapeutics and Vaccines Developers: Distribution by Phase of Development and Location of Headquarters
Figure 6.1 Company Competitiveness Analysis: mRNA Therapeutics and Vaccines Developers based in North America
Figure 6.2 Company Competitiveness Analysis: mRNA Therapeutics and Vaccines Developers based in Europe
Figure 6.3 Company Competitiveness Analysis: mRNA Therapeutics and Vaccines Developers based in Asia-Pacific and Rest of the World
Figure 8.1 Big Pharma Players: Distribution of Top Pharmaceutical Companies
Figure 8.2 Big Pharma Players: Distribution by Portfolio Diversity
Figure 8.3 Big Pharma Players: Distribution by Phase of Development
Figure 8.4 Big Pharma Players: Distribution by Target Therapeutic Areas
Figure 8.5 Spider Web Analysis: Amgen
Figure 8.6 Spider Web Analysis: AstraZeneca
Figure 8.7 Spider Web Analysis: Bayer
Figure 8.8 Spider Web Analysis: BioNTech
Figure 8.9 Spider Web Analysis: Eli Lilly
Figure 8.10 Spider Web Analysis: Gilead Sciences
Figure 8.11 Spider Web Analysis: GlaxoSmithKline
Figure 8.12 Spider Web Analysis: Merck
Figure 8.13 Spider Web Analysis: Moderna
Figure 8.14 Spider Web Analysis: Novartis
Figure 8.15 Spider Web Analysis: Novo Nordisk
Figure 8.16 Spider Web Analysis: Pfizer
Figure 8.17 Spider Web Analysis: Roche
Figure 8.18 Spider Web Analysis: Sanofi
Figure 8.19 Spider Web Analysis: Takeda
Figure 9.1 Startup-Health Indexing: Distribution by Location of Headquarters
Figure 9.2 Startup-Health Indexing: Distribution by Supplier Strength
Figure 9.3 Startup-Health Indexing: Distribution by Pipeline Maturity
Figure 9.4 Startup-Health Indexing: Distribution by Pipeline Strength
Figure 9.5 Startup-Health Indexing: Distribution by Financial Investments
Figure 9.6 Startup-Health Indexing: Distribution by Partnership Activity
Figure 9.7 Start-up Health Indexing: Roots Analysis Perspective
Figure 9.8 Start-up Health Indexing: Leading Companies
Figure 10.1 Clinical Trial Analysis: Distribution by Trial Registration Year, Pre-2017-2022
Figure 10.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
Figure 10.6 Clinical Trial Analysis: Distribution by Trial Status and Trial Phase
Figure 10.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 10.8 Clinical Trial Analysis: Distribution of Trials by Study Design
Figure 10.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 10.10 Most Active Players: Distribution by Number of Registered Trials
Figure 10.11 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 10.12 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geography
Figure 10.13 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geography
Figure 10.14 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2022
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 11.4 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 11.5 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Figure 11.6 Most Active Players: Distribution by Number of Partnerships
Figure 11.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.8 Partnerships and Collaborations: Local and International Agreements
Figure 12.1 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2015 - 2022
Figure 12.2 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested, Pre-2015 - 2022 (USD Million)
Figure 12.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 12.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 12.5 Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 12.6 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Therapeutic Area
Figure 12.7 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Geography (Continent-wise)
Figure 12.8 Funding and Investment Analysis: Regional Distribution of Instances (Country-wise)
Figure 12.9 Most Active Players: Distribution by Number of Funding Instances
Figure 12.10 Most Active Players: Distribution by Total Amount Raised (USD Million)
Figure 12.11 Most Active Investors: Distribution by Number of Funding Instances
Figure 12.12 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding
Figure 13.1 Patent Analysis: Distribution by Type of Patent
Figure 13.2 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2016-2022
Figure 13.3 Patent Analysis: Cumulative Distribution of Granted Patents by Publication Year, 2016-2022
Figure 13.4 Patent Analysis: Cumulative Distribution of Filed Patent Applications by Publication Year, 2016-2022
Figure 13.5 Patent Analysis: Distribution by Year-wise Filed Patent Applications and Granted Patents, 2016-2022
Figure 13.6 Patent Analysis: Cumulative Distribution of Patents by Publication Year and Type of Applicant, 2016-2022
Figure 13.7 Patent Analysis: Distribution by Patent Issuing Authority
Figure 13.8 Patent Analysis: Distribution by Patent Age
Figure 13.9 Patent Analysis: Distribution by CPC Sections
Figure 13.10 Patent Analysis: Leading Industry Players
Figure 13.11 Patent Analysis: Leading Non-Industry Players
Figure 13.12 Leading Inventors: Distribution by Number of Patents
Figure 13.13 Patent Benchmarking: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 13.14 mRNA Therapeutics and Vaccines: Patent Valuation
Figure 14.1 Global mRNA Therapeutics and Vaccines Market, 2022-2035 (USD Million)
Figure 14.2 mRNA Therapeutics and Vaccines Market: Distribution by Route of Administration, 2022, 2035 and 2035
Figure 14.3 mRNA Therapeutics and Vaccines Market: Distribution by Therapeutic Area, 2022, 2030 and 2035
Figure 14.4 mRNA Therapeutics and Vaccines Market: Distribution by Geography, 2022, 2030 and 2035
Figure 14.5 mRNA Therapeutics and Vaccines Market in North America, 2022-2035 (USD Million)
Figure 14.6 mRNA Therapeutics and Vaccines Market in the US, 2022-2035 (USD Million)
Figure 14.7 mRNA Therapeutics and Vaccines Market in Canada, 2022-2035 (USD Million)
Figure 14.8 mRNA Therapeutics and Vaccines Market in Mexico, 2022-2035 (USD Million)
Figure 14.9 mRNA Therapeutics and Vaccines Market in Europe, 2022-2035 (USD Million)
Figure 14.10 mRNA Therapeutics and Vaccines Market in the UK, 2022-2035 (USD Million)
Figure 14.11 mRNA Therapeutics and Vaccines Market in France, 2022-2035 (USD Million)
Figure 14.12 mRNA Therapeutics and Vaccines Market in Germany, 2022-2035 (USD Million)
Figure 14.13 mRNA Therapeutics and Vaccines Market in Italy, 2022-2035 (USD Million)
Figure 14.14 mRNA Therapeutics and Vaccines Market in Spain, 2022-2035 (USD Million)
Figure 14.15 mRNA Therapeutics and Vaccines Market in Rest of Europe, 2022-2035 (USD Million)
Figure 14.16 mRNA Therapeutics and Vaccines Market in Asia-Pacific, 2022-2035 (USD Million)
Figure 14.17 mRNA Therapeutics and Vaccines Market in India, 2022-2035 (USD Million)
Figure 14.18 mRNA Therapeutics and Vaccines Market in China, 2022-2035 (USD Million)
Figure 14.19 mRNA Therapeutics and Vaccines Market in Japan, 2022-2035 (USD Million)
Figure 14.20 mRNA Therapeutics and Vaccines Market in Australia, 2022-2035 (USD Million)
Figure 14.21 mRNA Therapeutics and Vaccines Market in Rest of Asia-Pacific, 2022-2035 (USD Million)
Figure 14.22 mRNA Therapeutics and Vaccines Market in Latin America, 2022-2035 (USD Million)
Figure 14.23 mRNA Therapeutics and Vaccines Market in Middle East and North Africa, 2022-2035 (USD Million)
Figure 14.24 Comirnaty Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.25 Spikevax Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.26 GEMCOVAC-19 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.27 ARCoV Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.28 CVnCoV Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.29 ARCT-154 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.30 mRNA-1345 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.31 mRNA-1647 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.32 mRNA-1010 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 15.1 Concluding Remarks: Overall Market Landscape
Figure 15.2 Concluding Remarks: Partnerships and Collaborations
Figure 15.3 Concluding Remarks: Funding and Investment Analysis
Figure 15.4 Concluding Remarks: Clinical Trial Analysis
Figure 15.5 Concluding Remarks: Patent Analysis
Figure 15.6 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 4.1 mRNA Therapeutics and Vaccines: Overall Market Overview
Table 4.2 mRNA Therapeutics and Vaccines: Information on Type of Delivery System Used
Table 4.3 mRNA Therapeutics and Vaccines: Information on Type of Molecule Encoded
Table 4.4 mRNA Therapeutics and Vaccines: Information on Route of Administration
Table 5.1 mRNA Therapeutics and Vaccines Developers: List of Companies
Table 7.1 Drug Profile: BNT162b2
Table 7.2 Drug Profile: mRNA-1273
Table 7.3 Drug Profile: GEMCOVAC-19
Table 7.4 Drug Profile: ARCoV
Table 7.5 Drug Profile: LUNAR-COV19
Table 7.6 Drug Profile: CVnCoV
Table 7.7 Drug Profile: mRNA-1010
Table 7.8 Drug Profile: mRNA-1345
Table 7.9 Drug Profile: mRNA-1647
Table 9.1 mRNA Therapeutics and Vaccines Start-ups: Information on Location of Headquarters
Table 11.1 mRNA Therapeutics and Vaccines: List of Partnerships and Collaborations
Table 11.2 mRNA Therapeutics and Vaccines: Information on Type of Agreement (Region-wise and Geography-wise), 2013-2022
Table 12.1 mRNA Therapeutics and Vaccines: List of Funding and Investments
Table 13.1 Patent Analysis: Top CPC Sections
Table 13.2 Patent Analysis: Top CPC Symbols
Table 13.3 Patent Analysis: Top CPC
Table 13.4 Patent Portfolio: Summary of Benchmarking Analysis
Table 13.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 13.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 14.1 mRNA Therapeutics and Vaccines: Expected Launch Year of Advance Stage Drug Candidates
Table 14.2 Comirnaty: Target Patient Population
Table 14.3 Comirnaty: Net Present Value (USD Million)
Table 14.4 Comirnaty: Value Creation Analysis (USD Million)
Table 14.5 Spikevax: Target Patient Population
Table 14.6 Spikevax: Net Present Value (USD Million)
Table 14.7 Spikevax: Value Creation Analysis (USD Million)
Table 14.8 GEMCOVAC-19: Target Patient Population
Table 14.9 GEMCOVAC-19: Net Present Value (USD Million)
Table 14.10 GEMCOVAC-19: Value Creation Analysis (USD Million)
Table 14.11 ARCoV: Target Patient Population
Table 14.12 ARCoV: Net Present Value (USD Million)
Table 14.13 ARCoV: Value Creation Analysis (USD Million)
Table 14.14 CVnCoV: Target Patient Population
Table 14.15 CVnCoV: Net Present Value (USD Million)
Table 14.16 CVnCoV: Value Creation Analysis (USD Million)
Table 14.17 ARCT-154: Target Patient Population
Table 14.18 ARCT-154: Net Present Value (USD Million)
Table 14.19 ARCT-154: Value Creation Analysis (USD Million)
Table 14.20 mRNA-1345: Target Patient Population
Table 14.21 mRNA-1345: Net Present Value (USD Million)
Table 14.22 mRNA-1345: Value Creation Analysis (USD Million)
Table 14.23 mRNA-1647: Target Patient Population
Table 14.24 mRNA-1647: Net Present Value (USD Million)
Table 14.25 mRNA-1647: Value Creation Analysis (USD Million)
Table 14.26 mRNA-1010: Target Patient Population
Table 14.27 mRNA-1010: Net Present Value (USD Million)
Table 14.28 mRNA-1010: Value Creation Analysis (USD Million)
Table 16.1 eTheRNA: Key Highlights
Table 17.1 mRNA Therapeutics and Vaccines: Distribution by Phase of Development
Table 17.2 mRNA Therapeutics and Vaccines: Distribution by Type of Drug Candidate
Table 17.3 mRNA Therapeutics and Vaccines: Distribution by Therapeutic Area
Table 17.4 mRNA Therapeutics and Vaccines: Distribution by Phase of Development and Therapeutic Area
Table 17.5 mRNA Therapeutics and Vaccines: Distribution by Type of Delivery System Used
Table 17.6 mRNA Therapeutics and Vaccines: Distribution by Type of Molecule Encoded
Table 17.7 mRNA Therapeutics and Vaccines: Distribution by Route of Administration
Table 17.8 mRNA Therapeutics and Vaccines: Distribution by Therapeutic Area and Route of Administration
Table 17.9 mRNA Therapeutics and Vaccines Developers: Distribution by Year of Establishment
Table 17.10 mRNA Therapeutics and Vaccines Developers: Distribution by Company Size
Table 17.11 mRNA Therapeutics and Vaccines Developers: Distribution by Location of Headquarters
Table 17.12 Key Players: Distribution by Number of Drug Candidates
Table 17.13 Key Players: Distribution by Phase of Development
Table 17.14 Key Players: Distribution by Therapeutic Area
Table 17.15 Big Pharma Players: Distribution by Portfolio Diversity
Table 17.16 Big Pharma Players: Distribution by Phase of Development
Table 17.17 Big Pharma Players: Distribution by Target Therapeutic Areas
Table 17.18 Startup-Health Indexing: Distribution by Location of Headquarters
Table 17.19 Startup-Health Indexing: Distribution by Supplier Strength
Table 17.20 Startup-Health Indexing: Distribution by Pipeline Maturity
Table 17.21 Startup-Health Indexing: Distribution by Pipeline Strength
Table 17.22 Startup-Health Indexing: Distribution by Financial Investments
Table 17.23 Startup-Health Indexing: Distribution by Partnership Activity
Table 17.24 Clinical Trial Analysis: Distribution by Trial Registration Year, Pre-2017-2022
Table 17.25 Clinical Trial Analysis: Distribution by Trial Status
Table 17.26 Clinical Trial Analysis: Distribution by Trial Phase
Table 17.27 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 17.28 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
Table 17.29 Clinical Trial Analysis: Distribution by Trial Status and Trial Phase
Table 17.30 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Table 17.31 Clinical Trial Analysis: Distribution by Study Design
Table 17.32 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 17.33 Most Active Players: Distribution by Number of Registered Trials
Table 17.34 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 17.35 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geography
Table 17.36 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geography
Table 17.37 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 17.38 Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2022
Table 17.39 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.40 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 17.41 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 17.42 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Table 17.43 Most Active Players: Distribution by Number of Partnerships
Table 17.44 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 17.45 Partnerships and Collaborations: Local and International Agreements
Table 17.46 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2015 - 2022
Table 17.47 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested, Pre-2015 - 2022 (USD Million)
Table 17.48 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 17.49 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 17.50 Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 17.51 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Therapeutic Area
Table 17.52 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Geography (Continent-wise)
Table 17.53 Funding and Investment Analysis: Regional Distribution of Instances (Country-wise)
Table 17.54 Most Active Players: Distribution by Number of Funding Instances
Table 17.55 Most Active Players: Distribution by Total Amount Raised
Table 17.56 Most Active Investors: Distribution by Number of Funding Instances
Table 17.57 Patent Analysis: Distribution by Type of Patent
Table 17.58 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2016-2022
Table 17.59 Patent Analysis: Cumulative Distribution of Granted Patents by Publication Year, 2016-2022
Table 17.60 Patent Analysis: Cumulative Distribution of Filed Patent Applications by Publication Year, 2016-2022
Table 17.61 Patent Analysis: Distribution by Year-wise Filed Patent Applications and Granted Patents, 2016-2022
Table 17.62 Patent Analysis: Cumulative Distribution of Patents by Publication Year and Type of Applicant, 2016-2022
Table 17.63 Patent Analysis: Distribution by Patent Issuing Authority
Table 17.64 Patent Analysis: Distribution by Patent Age
Table 17.65 Patent Analysis: Leading Industry Players
Table 17.66 Patent Analysis: Leading Non-Industry Players
Table 17.67 Leading Inventors: Distribution by Number of Patents
Table 17.68 mRNA Therapeutics and Vaccines: Patent Valuation
Table 17.69 Global mRNA Therapeutics and Vaccines Market, 2022-2035 (USD Million)
Table 17.70 mRNA Therapeutics and Vaccines Market: Distribution by Route of Administration, 2022, 2030 and 2035
Table 17.71 mRNA Therapeutics and Vaccines Market: Distribution by Therapeutic Area, 2022, 2030 and 2035
Table 17.72 mRNA Therapeutics and Vaccines Market: Distribution by Geography
Table 17.73 mRNA Therapeutics and Vaccines Market in North America, 2022-2035 (USD Million)
Table 17.74 mRNA Therapeutics and Vaccines Market in the US, 2022-2035 (USD Million)
Table 17.75 mRNA Therapeutics and Vaccines Market in Canada, 2022-2035 (USD Million)
Table 17.76 mRNA Therapeutics and Vaccines Market in Mexico, 2022-2035 (USD Million)
Table 17.77 mRNA Therapeutics and Vaccines Market in Europe, 2022-2035 (USD Million)
Table 17.78 mRNA Therapeutics and Vaccines Market in the UK, 2022-2035 (USD Million)
Table 17.79 mRNA Therapeutics and Vaccines Market in France, 2022-2035 (USD Million)
Table 17.80 mRNA Therapeutics and Vaccines Market in Germany, 2022-2035 (USD Million)
Table 17.81 mRNA Therapeutics and Vaccines Market in Italy, 2022-2035 (USD Million)
Table 17.82 mRNA Therapeutics and Vaccines Market in Spain, 2022-2035 (USD Million)
Table 17.83 mRNA Therapeutics and Vaccines Market in Rest of Europe, 2022-2035 (USD Million)
Table 17.84 mRNA Therapeutics and Vaccines Market in Asia-Pacific, 2022-2035 (USD Million)
Table 17.85 mRNA Therapeutics and Vaccines Market in India, 2022-2035 (USD Million)
Table 17.86 mRNA Therapeutics and Vaccines Market in China, 2022-2035 (USD Million)
Table 17.87 mRNA Therapeutics and Vaccines Market in Japan, 2022-2035 (USD Million)
Table 17.88 mRNA Therapeutics and Vaccines Market in Australia, 2022-2035 (USD Million)
Table 17.89 mRNA Therapeutics and Vaccines Market in Rest of Asia-Pacific, 2022-2035 (USD Million)
Table 17.90 mRNA Therapeutics and Vaccines Market in Latin America, 2022-2035 (USD Million)
Table 17.91 mRNA Therapeutics and Vaccines Market in Middle East and North Africa, 2022-2035 (USD Million)
Table 17.92 Comirnaty Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.93 Spikevax Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.94 GEMCOVAC-19 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.95 ARCoV Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.96 CVnCoV Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.97 ARCT-154 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.98 mRNA-1345 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.99 mRNA-1647 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.100 mRNA-1010 Sales Forecast: Base Scenario, Till 2035 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report:

1. 8VC
2. Abu Dhabi Investment Authority
3. ACM Biolabs
4. Acuitas Therapeutics
5. Adium Pharma
6. African Union
7. AIM Vaccine
8. Albany Molecular Research
9. Alcobra
10. Aldevron
11. Alexandria Venture Investments
12. Alexion Pharmaceuticals
13. Amazon Web Services
14. Amgen
15. Arcturus Therapeutics
16. ArrowMark Partners
17. Astellas
18. Astellas Innovation Management (Subsidiary of Astellas Pharma)
19. AstraZeneca
20. Atlas Venture
21. Avidity Partners
22. Axcelead
23. Baden-Württemberg Supply Institution for Doctors, Dentists and Veterinarians
24. Baidu
25. Baillie Gifford
26. Baird Capital
27. Baupost
28. Bavarian State Ministry for Economic Affairs, Regional Development and Energy
29. Baxter BioPharma Solutions
30. Bayer
31. BB Biotech
32. BeiGene
33. Bill & Melinda Gates Foundation
34. Biomedical Advanced Research and Development Authority
35. BioNTech
36. BIORCHESTRA
37. Biovac
38. Black Forest SICAV-SIF
39. BlueIO
40. Boehringer Ingelheim
41. Boehringer Ingelheim Venture Fund
42. BofA Securities
43. Boston Biotech Ventures
44. Brookside Capital
45. BVCF Management
46. BVF Partners
47. Cancer Research Institute
48. CanSino Biologics
49. Carlos III National Center for Cardiovascular Research (CNIC)
50. Catalent
51. CDH Investments
52. Central Innovation Programme for SMEs (ZIM)
53. Changhai Hospital
54. Charles River
55. Chartwave
56. Chiesi Farmaceutici
57. Chimeron Bio
58. China Growth Capital
59. China Merchants Medical and Health Industry Equity Fund
60. cmRNAbone consortium
61. Coalition for Epidemic Preparedness Innovations (CEPI)
62. Codex DNA
63. Colt Ventures
64. ConserV Bioscience
65. Continental Grain Company
66. Coppel family
67. Cormorant Asset Management
68. Co-win Ventures
69. CPE Yuanfeng
70. CSPC ZhongQi Pharmaceutical Technology
71. CureVac
72. Daiichi Sankyo
73. Daily Partners
74. Defense Advanced Research Projects Agency
75. dievini Hopp Biotech
76. Duke-NUS Medical School
77. E&Venture Partners
78. East Hospital Affiliated to Tongji University
79. EcoR1 Capital
80. EDBI
81. Eli Lilly
82. ELMA Investments
83. Emergent BioSolutions
84. eTheRNA
85. Ethris
86. Eurofarma
87. European Commission
88. European Investment Bank
89. European Investment Fund
90. European Union
91. Eurostars
92. Evercore
93. ExploRNA Therapeutics
94. Fall Line Capital
95. Fang Fund Partners
96. Fareva
97. Fidelity Management & Research Company
98. First Affiliated Hospital of Zhengzhou University
99. Flagship Ventures
100. Flanders Innovation & Entrepreneurship
101. Flu Lab
102. Fosun Pharma
103. Frazier Life Sciences Public Fund
104. Fudan University
105. Fund+
106. Gavi
107. Genentech
108. Genevant Sciences
109. Genmab
110. Gennova Biopharmaceuticals (Subsidiary of Emcure Pharmaceuticals)
111. GenScript ProBio
112. George Mason University
113. German Federal Government (Kreditanstalt für Wiederaufbau)
114. German Federal Ministry of Education and Research
115. German Pension Fund Baden-Württemberg
116. Ghent University
117. Gilead Sciences
118. GlaxoSmithKline
119. Government of Argentina
120. Government of Australia
121. Government of Brandenburg
122. Government of Canada
123. Government of Colombia
124. Government of Pennsylvania
125. Government of Peru
126. Government of South Korea
127. Government of Taiwan
128. Government of the Philippines
129. Government of the Republic of Botswana
130. Government of UK
131. Grand Decade Developments
132. GreenLight Biosciences
133. Greenwoods Investment
134. Gritstone bio
135. Gritstone Oncology
136. Harvard Medical School
137. Hatteras Venture Partners
138. HDT Bio
139. Hercules Capital
140. HHF Capital
141. High Forest Investment
142. High-Tech Gründerfonds
143. Honeywell
144. HongKong Hongrun Investment Development
145. Hunt Technology Ventures
146. I-Mab
147. Image Analysis Group
148. IMM Investment
149. Immorna
150. InnoRNA
151. InstaDeep
152. Institut Pasteur
153. Institute for Life Changing Medicines
154. Institute of Biomaterial Research of the Helmholtz-Zentrum Geesthacht
155. International AIDS Vaccine Initiative (IAVI)
156. Invus
157. Janssen Pharmaceuticals
158. Janus Henderson Investors
159. Jebsen Capital
160. Jefferies
161. Jeremy and Hannelore Grantham Environmental Trust
162. Jiuyou Capital
163. Johnson & Johnson
164. Julius Baer
165. Karolinska Institute
166. Karolinska University Hospital
167. Kernal Biologics
168. Körber
169. Landeskreditbank Baden-Württemberg – Förderbank
170. Lapam Capital
171. Laureus Capital
172. Leerink Partners
173. Lewis & Clark AgriFood
174. Liverna Therapeutics (Acquired by AIM Vaccine)
175. Longmen Capital
176. Lonza
177. LSK Investment
178. LSP
179. Ludwig Cancer Research
180. Lupa Systems
181. MassChallenge
182. Matinas BioPharma
183. MedImmune
184. Medison Pharma
185. MedLab Clinical
186. Merck
187. Mercurna
188. Ministry of Health Israel
189. Mirae Asset
190. MLS Capital Fund II
191. Moderna
192. Monsanto
193. Morningside
194. MPM Capital
195. MRL Ventures
196. Myeloid Therapeutics
197. Mymetics
198. myNEO
199. National Institutes of Health
200. Neon Therapeutics
201. Neurimmune
202. Newpath Partners
203. NH Investment & Securities
204. Novalis LifeSciences
205. Novartis
206. Novo Nordisk
207. Omega Funds
208. Omega Therapeutics
209. OrbiMed Advisors
210. Pantherna Therapeutics
211. Pfizer
212. Pfizer Venture Investments
213. Pharmaceutical Product Development
214. pHion Therapeutics
215. Pictet
216. Platinum Asset Management
217. PMV
218. Precision NanoSystems
219. Providence Therapeutics
220. PROVIREX
221. Qatar Investment Authority
222. Quantum Ventures Korea
223. RA Capital Management
224. Recipharm
225. ReCode Therapeutics
226. Redmile
227. Regeneron
228. Rejuvenation Technologies
229. Renap
230. Riesner Verwaltungs
231. Rivas Capital
232. RNACure
233. RNAimmune (Subsidiary of Sirnaomics)
234. Roche
235. Rock Springs Capital Management
236. Rotating Boulder Fund
237. ROVI
238. S2G Ventures
239. Samsung BioLogics
240. Sanofi
241. Sanofi Pasteur
242. SBI Investment
243. Sequoia Capital
244. Shanghai Jiao Tong University
245. Shanghai Junshi Biosciences
246. Shanghai Walga Biotechnology
247. Shenwan Hongyuan Capital
248. Shenzhen Kangtai Biological Products
249. Shire
250. SIGMA Group
251. Silicon Valley Bank
252. Singapore Government
253. Sirnaomics
254. Smilegate Investment
255. Smooth River
256. Spinnotec
257. Spruce Capital Partners
258. SR One
259. Stanford University
260. Steam Athena Capital
261. Stemirna Therapeutics
262. Struengmann Family Office
263. Suzhou Abogen Biosciences
264. Swiss Government
265. Tabuk Pharmaceuticals
266. Takeda
267. Tao Capital Partners
268. Temasek
269. Terra Magnum Capital Partners
270. Thermo Fisher Scientific
271. TransCode Therapeutics
272. Translate Bio
273. Turkish Republic Ministry of Health
274. Turn Biotechnologies
275. Ultragenyx Pharmaceutical
276. United Nations International Children's Emergency Fund (UNICEF)
277. University of Münster
278. University of Pennsylvania
279. University of Tokyo
280. US Government
281. Versant Ventures
282. Vertex Pharmaceuticals
283. Viceroy Research
284. Vida Ventures
285. Viking Global Investors
286. Vingroup
287. VitaDAO
288. WACKER
289. Walvax Biotechnology
290. Wellington Management Company
291. Widwin Investment
292. WuXi AppTec
293. Xeraya Capital
294. Yale University
295. Yijing Capital
296. Zheshang Venture Capital
297. Ziphius Vaccines
298. Zipline